- £170.78m
- £68.52m
- $38.63m
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Trading Update
MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte to Host Capital Markets Day Today
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Annual Report
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Appointment of Joint Corporate Broker
RCS - MaxCyte, Inc. - Save the Date: Capital Markets Day
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Second Price Monitoring Extn
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Price Monitoring Extension
Brief: MaxCyte Says Phase I Clinical Trial Of MCY-M11 Progressed
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Phase I Clinical Trial of MCY-M11 Progressed
RCS - MaxCyte, Inc. - ASGCT Presentation on First CARMA Drug Candidate
Brief: MaxCyte Inc FY Revenue $16.7 Mln
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Final Results for Year Ended 31 December 2018
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Launch of ExPERTT Instrument Family
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notice of Full Year Results
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Director Dealings
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options
Brief: Maxcyte Announces Multi-Drug Clinical & Commercial Agreement With Kite, A Gilead Company